SLC5A2 and diabetes mellitus: However, in view of the results of CVOTs showing a renoprotective effect of SGLT2 inhibitors among those with a wide range of renal function [10,11], currently treatment with SGLT2 inhibitors is rather also considered for patients with diabetes and renal dysfunction, i.e., eGFR ≥ 30 mL/min, to improve renal outcomes [4].